Patents for A61P 35 - Antineoplastic agents (221,099)
07/2009
07/30/2009US20090192134 Compounds
07/30/2009US20090192130 Method for Treating Uterine Fibroids
07/30/2009US20090192127 Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
07/30/2009US20090192112 Compositions and methods for treating cancer
07/30/2009US20090192111 miR-124 Regulated Genes and Pathways as Targets for Therapeutic Intervention
07/30/2009US20090192109 Compositions for diagnosis and therapy of diseases associated with aberrant expression of Kremen and/or Wnt
07/30/2009US20090192108 Gene overexpressed in cancer
07/30/2009US20090192107 Breast Cancer Markers
07/30/2009US20090192105 RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
07/30/2009US20090192102 miR-21 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
07/30/2009US20090192101 Cancer-specific promoters
07/30/2009US20090192098 Method for treating hematopoietic neoplasms
07/30/2009US20090192089 treatment of cell damage caused by ischemia or stroke by administering to a cell or a tissue an effective amount of an isozyme specific delta PKC (protein kinase C) antagonist
07/30/2009US20090192088 Vascular Endothelial Growth Factor 2
07/30/2009US20090192087 Methods and Compositions Using Klotho-FGF Fusion Polypeptides
07/30/2009US20090192085 FKBP-L And Uses Thereof
07/30/2009US20090191640 Methods of Screening for Atherosclerosis
07/30/2009US20090191572 Imaging, diagnosis and treatment of disease
07/30/2009US20090191262 Use of compounds of formula a-r-xo pharmaceutically acceptable salts thereof for producing a pharmaceutically preparations
07/30/2009US20090191237 Methods and reagents for vaccination which generate A CD8 T cell immune response
07/30/2009US20090191232 Combination therapy for the treatment of tumors
07/30/2009US20090191230 Cascade
07/30/2009US20090191225 Fusion proteins; homogeneous purity, and unaltered affinity, and can be produced in high yields without the requirement of extensive purification; stable in serum to allow in vivo applications
07/30/2009US20090191224 Nucleolin-Mediated Cancer Diagnostics and Therapy
07/30/2009US20090191215 Treatment with anti-VEGF Antibodies
07/30/2009US20090191211 METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES
07/30/2009US20090191210 Method for inhibiting tumor invasion or spreading in a subject
07/30/2009US20090191201 Combination of the application of antibodies for immunostimulation together with glucocorticoids
07/30/2009US20090191197 Cancerous disease modifying antibodies
07/30/2009US20090191193 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof
07/30/2009US20090191188 Immunostimulatory nucleic acids
07/30/2009US20090191181 Methods of modulating smyd3 for treatment of cancer
07/30/2009US20090191172 Method of Controlling Administration of Cancer Antigen
07/30/2009US20090191160 Methods of producing pluripotent stem-like cells
07/30/2009US20090191152 Intralymphatic chemotherapy drug carriers
07/30/2009US20090191146 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
07/30/2009US20090191130 De novo synthesis of bacteriochlorins
07/30/2009US20090191118 Cytotoxicity mediation of cells evidencing surface expression of TROP-2
07/30/2009US20090191117 Anti-Integrin Antibodies, Compositions, Methods and Uses
07/30/2009DE102007057718A1 New heteroaryl-substituted piperidine compounds are protease-activated receptor antagonists useful for the treatment and/or prophylaxis of e.g. cardiovascular diseases, thromboembolic diseases, tumors, stroke, hypertension and asthma
07/30/2009CA2713137A1 Targeting of innate immune response to tumor site
07/30/2009CA2713126A1 Lytic domain fusion constructs and methods of making and using same
07/30/2009CA2713111A1 4-pyridinone compounds and their use for cancer
07/30/2009CA2712959A1 Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
07/30/2009CA2712791A1 Fused pyridines active as inhibitors of c-met
07/30/2009CA2712748A1 13,13-dimethyl-des-c,d analogs of 1.alpha.,25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof
07/30/2009CA2712612A1 4-(pyrrolo[2,3-c]pyridine-3-yl)pyrimidin-2-ylamine derivatives
07/30/2009CA2712604A1 Iap inhibitors
07/30/2009CA2712388A1 Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
07/30/2009CA2712087A1 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib
07/30/2009CA2711629A1 Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses
07/30/2009CA2709806A1 Protein kinase inhibitors and use thereof
07/30/2009CA2708175A1 Phthalazinone derivatives
07/30/2009CA2704128A1 Novel composition for treating the side effects of anticancer treatments
07/29/2009EP2083272A1 Cancer cell identification marker and cancer cell proliferation inhibitor
07/29/2009EP2083076A1 In vitro differentiation/induction of lymphocyte from stem cell having genotype provided after gene reconstitution
07/29/2009EP2083018A2 Compositions and methods relating to STOP-1
07/29/2009EP2083014A2 Inhibitors of interleukin-1ß converting enzyme
07/29/2009EP2083011A1 Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof
07/29/2009EP2083005A1 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
07/29/2009EP2082754A1 Bone defect filler, release-controlled carrier, and their production methods
07/29/2009EP2082746A1 Extract from Urginea Maritima for use in the treatment of non small cell lung cancer (NSCLC) and other solid tumors
07/29/2009EP2082745A1 Method for cancer therapy with a parvovirus combined with chemotherapy
07/29/2009EP2082740A2 Use of imidazole derivatives as MDR modulators
07/29/2009EP2082737A2 Methods of inducing terminal differentiation
07/29/2009EP2081964A2 Alginate and alginate lyase compositions and methods of use
07/29/2009EP2081962A2 Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
07/29/2009EP2081938A2 Substituted 8-piperidinyl-2-pyridinyl-pyrimido ý1,2-a¨pirimidin-6-one and 8-piperidinyl-2-pyrimidi nyl-pyrimidoý1,2,-a¨pyrimidin-6-one derivatives
07/29/2009EP2081937A2 Triazolopyridazine protein kinase modulators
07/29/2009EP2081931A2 Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
07/29/2009EP2081928A2 Pyrrolo-pyridine kinase inhibitors
07/29/2009EP2081918A2 Mitotic kinesin inhibitors and methods of use thereof
07/29/2009EP2081902A1 Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
07/29/2009EP2081895A1 Hydrobenzamide derivatives as inhibitors of hsp90
07/29/2009EP2081599A2 Compounds, kits and methods for conferring cytoprotection
07/29/2009EP2081595A2 Combination treatment of cd38-expressing tumors
07/29/2009EP2081590A2 Cancer stem cell-targeted cancer therapy
07/29/2009EP2081586A1 Rspondins as modulators of angiogenesis and vasculogenesis
07/29/2009EP2081565A2 Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
07/29/2009EP2081556A1 Stable imatinib compositions
07/29/2009EP1807407B1 Aromatic amides as inhibitors of c-fms kinase
07/29/2009EP1771177A4 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
07/29/2009EP1729824B1 Phospholipid analogs for the treatment of cancers
07/29/2009EP1641791B1 3-(guanidinocarbonyl)heterocycle derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions including them
07/29/2009EP1549679B1 Fusion protein comprising angiopoietin receptor-binding and a multimerization domain
07/29/2009EP1517911B1 Tumour-inhibiting platinum (ii) oxalate complexes
07/29/2009EP1495014B1 Flavanoids derivatives as chemotherapeutic, chemopreventive, and antiangiogenic agents
07/29/2009EP1455772B1 Medium for radical treatment of tumors, inflammatory processes, fungal infections and other affections of the tissues, diagnostic and prophylactic and method of its implementation
07/29/2009EP1432441B1 Use of hmgb1 for the activation of dendritic cells
07/29/2009EP1406608B1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
07/29/2009EP1401473B1 Transporters comprising spaced arginine moieties
07/29/2009EP1399221B1 Compositions comprising oestrone-3-o-sulphamate and trail (tnf-related apoptosis inducing ligand)
07/29/2009EP1347805B1 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
07/29/2009EP1261601B1 Substituted indoles for modulating nfkb activity
07/29/2009EP1189641B1 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
07/29/2009EP1086223B1 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
07/29/2009EP1036327B1 HLA-E binding to CD94/NKG2+ cells
07/29/2009CN101491536A Therapeutically useful synthetic oligonucleotides
07/29/2009CN100519559C 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents
07/29/2009CN100519555C Novel indole derivative for alkylating specific base sequence of DNA, alkylating agent using the same and medicament